Startup profile · funding coverage
Genesis Therapeutics
AI molecular discovery company for small-molecule drug design (now Genesis Molecular AI).
Stage
series b
Status
private
Coverage
full
Why Genesis Therapeutics is interesting
Genesis pioneered physics-informed generative AI for drug discovery; a16z led seed and co-led a $200M Series B with Menlo Ventures before the company rebranded to Genesis Molecular AI.
Key facts
- Series A (2020): $52M led by Rock Springs with Menlo Ventures (/fund/menlo-ventures) and a16z seed lead (BioSpace)
- Series B (Aug 2023): $200M co-led by a16z Bio+Health (/fund/andreessen-horowitz) and Menlo Ventures (BusinessWire)
- Rebranded to Genesis Molecular AI; pharma deals with Genentech and Eli Lilly
Investors in our directory
Funds linked from Genesis Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences AI & Machine Learning
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Genesis Therapeutics
Funding context and why this company shows up in venture coverage.
Genesis Therapeutics (now Genesis Molecular AI) develops the GEMS platform for AI-driven small-molecule drug discovery — using generative models and physics-based simulation to design drug candidates.
Andreessen Horowitz (/fund/andreessen-horowitz) led Genesis's seed round and co-led its $200M Series B (2023) with Menlo Ventures (/fund/menlo-ventures). Rock Springs led the $52M Series A (2020).
Genesis Therapeutics is at Series B based on its August 2023 $200M round, before rebranding to Genesis Molecular AI.
Genesis was an early mover in combining physics-informed models with generative AI for small-molecule design — with pharma partnerships at Genentech and Eli Lilly validating the approach.
No. The company rebranded to Genesis Molecular AI. See also /startup/genesis-molecular-ai in this directory.
Last updated: 2026-07-24